Intersect ENT (NSDQ:XENT) shares dipped today on fourth-quarter losses that topped the consensus forecast. The Menlo Park, Calif.-based ear, nose and throat condition treatment developer posted losses of -$7.96 million, or -25¢ per share, on sales of $31.75 million for the three months ended Dec. 31, 2019, for a nearly $3 million bottom-line slide on a … Continue reading Intersect ENT’s Q4 beats Street despite losses